Etsy Inc vs Novartis AG — how do they compare? Etsy Inc trades at $74.75 (market cap $6.90B), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 38.9× Etsy Inc's market cap, and Novartis AG pays a 3.31% dividend while Etsy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Novartis AG for 82 Days on average.
| ETSY | NVS | |
|---|---|---|
Market Cap | $6.90B | $268.57B |
Volume | 2,923,867 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $168.62 |
52-Week Low | $44.05 | $121.80 |
Typical Hold Time | 67 Days | 82 Days |
Enterprise Value | $8.85B | $309.89B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $71.49, up 0.14% with a bearish technical signal despite recent earnings beats. The company maintains strong gross margins at 71.4% but faces declining net income margins from 10.79% in 2024 to 5.65% in 2025. Recent positive developments include AI integration initiatives and payment partnership renewals, while technical indicators show resistance near $72-$74 levels.
Wall Street maintains a bullish consensus with 53% buy ratings and $85.94 price target, representing 20% upside potential. However, negative shareholder equity and high debt levels pose significant balance sheet risks. The stock's valuation appears reasonable at 23.78 P/E, but execution on AI initiatives and margin stabilization will be critical for sustained growth.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →